Open an account

AxoGen

AXGN · NASDAQ

$36.17+$0.93 (+2.64%)TodayMarket closed ·
Prev close $35.24

About AXGN

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.

Employees
622
Headquarters
Alachua, Florida
Listed
Dec 17, 1986
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
axogeninc.com

AXGN key statistics

Market cap
2.12B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.46M
Volume
974.45K
Open price
$35.71
High today
$36.84
Low today
$35.56
52 Week high
$52.91
52 Week low
$16.65

AxoGen (AXGN) at a glance

As of Oct 20, 2026, AxoGen (AXGN) shares are priced at $36.17, giving the company a market cap of 2.12B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $35.56 and $36.84. The current price is 1.7% above the day's low and 1.8% below its high.

Volume so far is 974.45K shares, below the average of 1.46M shares a day.

Over the past year AxoGen has ranged from $16.65 to $52.91, and now sits 54% of the way up that range.

AxoGen met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.12 per share against an estimate of $0.1239.

The average analyst price target is $54.77, 51.4% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 12 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 12 analystsAvg $54.77
Low
$48.48
Now
$36.17
High
$60.90

AXGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 348.2% on average.

  1. Q3 FY24: reported $0.07 per share against an estimate of $0.0057
  2. Q4 FY24: reported $0.07 per share against an estimate of $0.0326
  3. Q1 FY25: reported -$0.02 per share against an estimate of $0.0163
  4. Q2 FY25: reported $0.12 per share against an estimate of $0.0646
  5. Q3 FY25: reported $0.12 per share against an estimate of $0.0731
  6. Q4 FY25: reported $0.07 per share against an estimate of $0.0991
  7. Q1 FY26: reported $0.07 per share against an estimate of $0.0733
  8. Q2 FY26: reported $0.12 per share against an estimate of $0.1239

AXGN news

  • Press releaseGlobe Newswire

    Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

  • Press releasePRNewswire

    Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Vandana Singh

    Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

  • Press releaseGlobe Newswire

    Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

  • Press releaseGlobe Newswire

    Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

  • Press releasePRNewswire

    Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

  • Press releaseGlobe Newswire

    The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself

Similar companies

Companies in the same industry as AxoGen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.